Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

3-Fluoro-PCP

From Wikipedia, the free encyclopedia
(Redirected from 3F-PCP)
3-Fluoro-PCP
Legal status
Legal status
Identifiers
  • 1-[1-(3-fluorophenyl)cyclohexyl]piperidine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H24FN
Molar mass261.384 g·mol−1
3D model (JSmol)
  • Fc1cccc(c1)C1(CCCCC1)N1CCCCC1
  • InChI=1S/C17H24FN/c18-16-9-7-8-15(14-16)17(10-3-1-4-11-17)19-12-5-2-6-13-19/h7-9,14H,1-6,10-13H2
  • Key:PFPLGKFWWBXTNP-UHFFFAOYSA-N

3-Fluoro-PCP (3'-F-PCP, 3F-PCP) is a recreational designer drug from the arylcyclohexylamine family, with dissociative effects.[1][2][3] It was first identified in Slovenia in October 2020,[4] and was made illegal in Hungary in April 2021.[5]

See also

[edit source]

References

[edit source]
  1. Cone EJ, McQuinn RL, Shannon HE (January 1984). "Structure-activity relationship studies of phencyclidine derivatives in rats". The Journal of Pharmacology and Experimental Therapeutics. 228 (1): 147–53. doi:10.1016/S0022-3565(25)21490-2. PMID 6694098.
  2. Ogunbadeniyi AM, Adejare A (2002). "Syntheses of fluorinated phencyclidine analogs". Journal of Fluorine Chemistry. 114 (1): 39–42. Bibcode:2002JFluC.114...39O. doi:10.1016/S0022-1139(01)00565-6.
  3. Catalani V, Arillotta D, Corkery JM, Guirguis A, Vento A, Schifano F (2020). "Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach". Frontiers in Psychiatry. 11 632405. doi:10.3389/fpsyt.2020.632405. PMC 7900492. PMID 33633599.
  4. Analytical Report. 3F-PCP (C17H24FN). 1-(1-(3-fluorophenyl)cyclohexyl)piperidine. National Forensic Laboratory, Slovenia
  5. "Amendment of Minister for Human Capacities Decree No 55/2014 of 30 December 2014 on substances or groups of compounds classified as new psychoactive substances, 2021/225/HU".